Abstract
Quick release formulation of Bromocriptine mesylate is recently been approved by FDA (Food and Drug Administration) for the treatment of type 2 diabetes mellitus. Early morning dose of bromocriptine mesylate reduces the plasma prolactin level and increases the hypothalamic dopaminergic drive thereby reducing postprandial plasma glucose, triglyceride, and free fatty acid concentrations. Conventional preparation of bromocriptine are available in 2.5 mg or 5 mg tablets used for hyperprolactinemia and suppression of lactation. Studies have shown that quick release bromocriptine given in dose of 0.8-4.8 mg per day for a period of 6 month have successfully achieved target blood sugar. So the drug is well tolerated in antidiabetic dosage with mild side effects like nausea vomiting and fatigue. The central mechanism of action , good side effect profile and its effects to reduce adverse cardiovascular outcomes make it an attractive option for treatment of type 2 diabetes.  Key words : Bromociptine, diabetes, insulin resistance, quick release formulation, prolactin
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
